Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,clopidogrel hydrogen sulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,clopidogrel hydrogen sulfate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - aspirin -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - aspirin; paracetamol; caffeine - oral tablet - 300mg ; 200mg ; 45mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg); aspirin, quantity: 100 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; stearic acid; carnauba wax; hyprolose; colloidal anhydrous silica; maize starch; hydrogenated castor oil; macrogol 6000; mannitol; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - duocover is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). duocover is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, duocover has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg); aspirin, quantity: 100 mg - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; microcrystalline cellulose; maize starch; macrogol 6000; stearic acid; mannitol; carnauba wax; hydrogenated castor oil; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - duoplidogrel is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). duoplidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, duoplidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - aspirin, quantity: 300 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; stearic acid; hyprolose; colloidal anhydrous silica - for the temporary relief from pain associated with headaches and migraine headaches, rheumatic and arthritic pain, fibrositis, neuralgia, toothache, cold and flu sysmptoms, sore throats and period pain. relieves inflammation associated with back and muscular pain, strains and sprains. reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - aspirin, quantity: 100 mg - tablet, enteric coated - excipient ingredients: guar gum; hypromellose; purified talc; glycerol; titanium dioxide; colloidal anhydrous silica; triethyl citrate; sodium lauryl sulfate; methacrylic acid copolymer; sodium bicarbonate; sunset yellow fcf aluminium lake; macrogol 3350 - for the treatment of patients with known cardiovascular or cerebrovascular disease, as an antiplatelet agent for prophylaxis against acute myocardial infarction, unstable angina, transient ischaemic attack and cerebrovascular accident (stroke).

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - aspirin, quantity: 100 mg - tablet, enteric coated - excipient ingredients: guar gum; titanium dioxide; colloidal anhydrous silica; purified talc; triethyl citrate; sodium lauryl sulfate; methacrylic acid copolymer; sodium bicarbonate; hypromellose; glycerol; sunset yellow fcf; quinoline yellow; polyvinyl alcohol; macrogol 3000 - for the treatment of patients with known cardiovascular or cerebrovascular disease, as an antiplatelet agent for prophylaxis against acute myocardial infarction, unstable angina, transient ischaemic attack and cerebrovascular accident (stroke).

Australia - English - Department of Health (Therapeutic Goods Administration)

sigma company limited - aspirin, quantity: 100.008 mg - tablet, enteric coated - excipient ingredients: citric acid; microcrystalline cellulose; purified water; titanium dioxide; carbomer 941; sodium hydroxide; pregelatinised maize starch; maize starch; stearic acid; betadex; macrogol 6000; sunset yellow fcf aluminium lake; purified talc; methacrylic acid copolymer; hypromellose; xanthan gum; polyvinyl alcohol; lecithin - for the treatment of patients with known cardiovascular or cerebrovascular disease an antiplatelet agent for prophylaxis against acute myocardial infarction, unstable angina, transient ischaemic attack and cerebrovascular accident (stroke)